0714/25SCR019-18/R10RGB
Media Highlights
From the 2025 ASCO® Annual Meeting
2
Media Outlet Article / Coverage
American Journal of Managed
Care
March Toward More Tailored Treatments Continues at ASCO 2025
American Journal of Managed
Care
Breaking Ground in Breast Cancer: A New Standard in TNBC, a New
Way to Target ESR1
American Medical Journal
Interview with Erika Hamilton
The ASCO Post
Vepdegestrant Improves Progression-Free Survival in Select
Patients With ESR1-Mutant Advanced Breast Cancer
The ASCO Post
Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced
Breast Cancer: Vepdegestrant vs Fulvestrant
The ASCO Post
Vepdegestrant vs Fulvestrant in Estrogen Receptor–Positive, HER2-
Negative Advanced Breast Cancer
Breast Cancer Research
Foundation
5 Breast Cancer Highlights to Know About From ASCO 2025
Breast Cancers Today
Dr. Erika Hamilton on VERITAC-2: Vepdegestrant Shows PFS Benefit
in ESR1m ER+/HER2- Breast Cancer
Breaking the News
Pfizer, Arvinas Report Positive Breast Cancer Drug Trial
Cancer Therapy Advisor
Breast Cancer Highlights From ASCO 2025
docwirenews
Emi-Le ADC Targets B7-H4 in TNBC and Beyond: Promising Early
Efficacy with Novel Payload
eCancer
Vepdegestrant Could Extend PFS for Some ESR1-mutated
Advanced Breast Cancers
Endpoints News
Arvinas, Pfizer's PROTAC in Breast Cancer No Better Than Oral
SERDs
Healio/HemOnc Today
Vepdegestrant May Benefit Certain Patients With Advanced Breast
Cancer With ESR1 Mutation
Healthbook
Dr Erika Hamilton Highlights the Key Breast Cancer Studies
Presented at 2025 ASCO Annual Meeting
Medscape
Which Class of ER Degrader Is Better for ER+/HER2- Breast Cancer?
MedPage Today
Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in
Second-Line
MedSpoke
Conversations in BC w/ Dr. Hamilton
New England Journal of
Medicine
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in
Advanced Breast Cancer
OncLive
Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+ HER2-Negative
Advanced Breast Cancer
OncLive
Five Under 5: Top Oncology Videos for the Week of 6/1
Erika Hamilton, MD
SCRI
Continued ➔
